4Basebio

4Basebio ROA

The Return on Assets (ROA) of 4Basebio (4BB.L) as of Nov 1, 2026 is -57.21 %. In the previous year, Return on Assets (ROA) was -27.57 % — a change of 107.48% (lower).

ROA

-57.21 %

YoY

107.48%

Last updated:

In 2025, 4Basebio's return on assets (ROA) was -57.21 %, a 107.48% increase from the -27.57 % ROA in the previous year.

The 4Basebio ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-36.62 GBP
Jan 1, 2020
-4.04 GBP
Jan 1, 2021
-22.00 GBP
Jan 1, 2022
-44.06 GBP
Jan 1, 2023
-64.29 GBP
Jan 1, 2024
-27.57 GBP
Jan 1, 2025
-57.21 GBP
The 4Basebio ROA history
YEARROAYoY
-57.21 %+107.48%
-27.57 %-57.11%
-64.29 %+45.93%
-44.06 %+100.23%
-22.00 %+445.02%
-4.04 %-88.98%
-36.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

4Basebio Stock analysis

What does 4Basebio do? 4basebio Plc develops advanced therapy medicinal products using synthetic DNA and non-viral delivery platforms for cell and gene therapies, DNA vaccines, and mRNA solutions. The company manufactures application-specific synthetic DNA for research, therapeutic, and pharmacological use, while also creating non-viral vectors for efficient payload delivery. Its technology enables the production of synthetic DNA constructs, mRNA, and vectors for cell and tissue-specific delivery, targeting applications such as AAV and Lentivirus viral vectors, mRNA vaccines, genome editing, and DNA vaccines. The company focuses on exploiting intellectual property in cell and gene therapies and DNA vaccines to drive innovation and commercialization. The primary customers for 4basebio Plc's products include research institutions, biotechnology firms, and pharmaceutical companies seeking advanced therapeutic solutions. These entities purchase synthetic DNA constructs, non-viral delivery vectors, and specialized DNA-based products for use in developing cell and gene therapies, DNA vaccines, and mRNA therapeutics. The company's offerings are tailored to support the development of safe and effective treatments across multiple therapeutic areas. 4basebio Plc's revenue streams are derived from the manufacturing and supply of synthetic DNA products, non-viral delivery platforms, and intellectual property licensing. The company generates income through the sale of application-specific synthetic DNA for research and therapeutic applications, as well as the development of delivery vectors for targeted therapies. By leveraging its proprietary technology in DNA synthesis and payload delivery, 4basebio Plc positions itself as a key provider of essential components for next-generation biologics and vaccines. 4Basebio is one of the most popular companies on Eulerpool.

ROA Details

Understanding 4Basebio's Return on Assets (ROA)

4Basebio's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing 4Basebio's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider 4Basebio's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in 4Basebio’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about 4Basebio stock

Return on Assets (ROA) of 4Basebio is -57.21 % in 2025.

Return on Assets (ROA) of 4Basebio changed from -27.57 % to -57.21 %, representing a 107.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) 4Basebio since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s 4Basebio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — 4Basebio

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — 4Basebio